Patient Condition
Chagas cardiomyopathy resulted in HFrEF, LVEF 26%, NYHA class III, and concurrent ventricular arrhythmia. Sequela of Trypanosoma cruzi infection and significant expansion of the heart.
Treatment Timeline
| Phase | Details | Date |
|---|
| integrated assessment | | |
| Drug optimization and heart rhythm management | | |
| Heart failure recovery | | |
| maintenance treatment | | |
Treatment Outcome
| before | LVEF 26%, NYHA class III, NT-proBNP 5100 pg/mL, ventricular premature beats>10000 beats/24h |
|---|
| after | LVEF 42%, NYHA class II, NT-proBNP 1600 pg/mL, ventricular premature beats <2000 beats/24h |
|---|
| highlight | Combined treatment with ARNI+ SGLT2i increased LVEF by 16% and significantly reduced ventricular arrhythmia |
|---|